> >

Grant Information

Grant ID	DP260239
Awarded On	November 19, 2025
Title	Non-invasive oscillatory magnetic field therapy for the treatment of brain cancers
Program	Product Development Research
Award Mechanism	Texas Diagnostic and Devices Company Awards for Product Development Research
Institution/Organization	OncoMAGNETx, Inc.
Principal Investigator/Program Director	Ashok Gowda
Cancer Sites	Brain and Other Nervous System
Contracted Amount	$13970678
Lay Summary	OncoMAGNETx (OMTx), a Houston-based company, is developing a wearable non-invasive medical device to treat glioblastoma (GBM), the most aggressive and deadly brain cancer. With a poor median survival of 12–18 months, GBM is a huge unmet need known for lack of viable treatments, despite much effort. Most therapies fail as they are invasive and/or localized, and cannot address the manner by which GBM aggressively spreads. Our device was invented at Houston Methodist, has no harmful side effects, and is worn for 4–6 hrs/day at home. Low-intensity rotating magnetic fields target cancer cells by disrupting metabolism and causing GBM tumor cell death, all while sparing healthy and surrounding tiss... Read More OncoMAGNETx (OMTx), a Houston-based company, is developing a wearable non-invasive medical device to treat glioblastoma (GBM), the most aggressive and deadly brain cancer. With a poor median survival of 12–18 months, GBM is a huge unmet need known for lack of viable treatments, despite much effort. Most therapies fail as they are invasive and/or localized, and cannot address the manner by which GBM aggressively spreads. Our device was invented at Houston Methodist, has no harmful side effects, and is worn for 4–6 hrs/day at home. Low-intensity rotating magnetic fields target cancer cells by disrupting metabolism and causing GBM tumor cell death, all while sparing healthy and surrounding tissue. In 11 end-stage GBM patients treated under compassionate-use at Houston Methodist Hospital, 73% saw significant tumor reduction without any serious device-related side effects. CPRIT funds will help complete FDA-required safety testing, optimize device comfort/usability, and launch formal U.S. clinical studies. . Our project is heavily Texas-based, with manufacturing at Biotex (Houston) and multiple clinical trial sites planned within the state. This work directly supports CPRIT’s mission by addressing a critical gap in brain cancer treatment, advancing a Texas-based oncology innovation, and laying groundwork for a scalable cancer device industry as part of the Texas ecosystem. OMTx could greatly improve care and outcomes for patients facing this devastating disease. Read Less